Management of a Mildly Suppressed TSH (0.26 µIU/mL)

Immediate Assessment

• Verify that the low TSH is persistent before initiating any work‑up or therapy, because transient suppression is common in non‑thyroidal illness, certain medications, or assay interference. 1

Confirmatory Testing (within 4 weeks)

• Repeat TSH together with free T4 and total T3 to confirm whether the abnormality is sustained and to differentiate subclinical from overt hyperthyroidism. 1
• If the patient has cardiac symptoms (e.g., tachycardia, palpitations, atrial fibrillation), overt hyperthyroid signs (tremor, weight loss, heat intolerance), or any urgent medical issue, shorten the repeat‑testing interval to days or 1–2 weeks. 1

Interpretation of a TSH = 0.26 µIU/mL

• A TSH of 0.26 µIU/mL lies in the mildly suppressed range (0.1–0.45 mIU/L). This may represent subclinical hyperthyroidism when free T4 and T3 are normal, or early overt hyperthyroidism when either hormone is elevated. 1

Risk Stratification & Treatment Decisions

Subclinical Hyperthyroidism (TSH 0.1–0.45 mIU/L, normal free T4 & T3)

• Routine treatment is not recommended for all patients in this range because current evidence does not demonstrate a clear link between this degree of TSH suppression and adverse outcomes. 1
• Consider treatment in high‑risk groups: individuals >60–65 years old, patients with known cardiovascular disease, post‑menopausal women at risk for osteoporosis, or those who are symptomatic. 1
• When treatment is contemplated—or when the patient belongs to a high‑risk group—proceed with an etiologic work‑up to identify the underlying cause. 1

More Severe Subclinical Hyperthyroidism (TSH < 0.1 mIU/L, normal free T4 & T3)

• Treatment should be considered for patients >60 years, those with heart disease, osteopenia/osteoporosis, or any hyperthyroid symptoms, given the substantially increased risk of atrial fibrillation and bone loss. 1
• An etiologic work‑up is required to differentiate Graves disease, toxic nodular goiter, or destructive thyroiditis. 1

Overt Hyperthyroidism (elevated free T4 and/or total T3)

• Overt thyrotoxicosis mandates definitive therapy irrespective of symptom severity because of the high risk of atrial fibrillation, embolic stroke, heart failure, osteoporosis, and increased mortality. 1
• Initiate urgent etiologic work‑up (see below) to guide definitive treatment selection. 1

Etiologic Work‑up (when treatment is planned or overt disease is confirmed)

• Obtain a radioactive iodine uptake (RAIU) scan to distinguish:
  
  • Diffuse uptake → Graves disease
  • Focal uptake → Toxic adenoma
  • Heterogeneous uptake → Toxic multinodular goiter
  • Low uptake → Destructive thyroiditis
  • (All supported by JAMA guidance.) 1